José Ignacio Chacón

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Emilio Alba, Lourdes Calvo, Joan Albanell et al. · Annals of Oncology · 2012 · 226 citations · Full text

Medicine, Oncology, Breast Oncology +14

Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients

José Ignacio Chacón, Manuela Mollejo, Enriqueta Muñoz et al. · Blood · 2002 · 201 citations · Full text

Medicine, Oncology, Pathology +14

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

Ángela Santonja, Alfonso Sánchez‐Muñoz, Aňa Lluch et al. · Oncotarget · 2018 · 186 citations · Full text

Medicine, Oncology, Breast Oncology +15